Jm. Dominguez et al., IN-111-CYT-103 SCANNING IN RECURRENT COLORECTAL-CANCER - DOES IT AFFECT STANDARD MANAGEMENT, Diseases of the colon & rectum, 39(5), 1996, pp. 514-519
PURPOSE: In a blinded fashion, radiolabeled B72.3 was investigated in
operative cases of recurrent colorectal cancer to determine if diagnos
tic accuracy would be improved to ultimately maximize curability and m
inimize interventional morbidities. METHODS: Study patients underwent
conventional evaluation including history, physical examination, abdom
inal/pelvic computed tomographic scan (CT), colon examination, and car
cinoembryronic antigen (CEA) determination, with select magnetic reson
ance imaging and ultrasonographic imaging as indicated. Murine monoclo
nal antibody B72.3 was labeled with indium-111 (In-111-CYT-103 provide
d by Cytogen) and scans obtained at 48 hours and, selectively, at 72 a
nd 96 hours. Unlike previous studies, the operating surgeon was blinde
d to In-111-CYT-103 abdominal scan results until surgical exploration
was complete. RESULTS: Of 15 study patients (10 male; 5 female), avera
ge age was 57 years, and average CEA was 10 ng/ml (with eight elevated
CEA levels). A single patient did not undergo surgery because of pres
ence of pulmonary metastases identified on CT scan but not identified
on a In-111-CYT-103 scan. Laparotomies included resection and intraope
rative radiation (10), resection alone (1), and biopsy only (3). CT an
d In-111-CYT-103 scans were compared with operative findings. CT scans
had an accuracy and positive predictive value of 47 and 100 percent,
respectively, whereas those of In-111-CYT-103 scan were 60 and 82 perc
ent, respectively. Contribution of the scan to diagnosis and managemen
t was graded by the surgeon as no effect (67 percent), beneficial effe
ct (13 percent), or negative effect (20 percent). CONCLUSIONS: In-111-
CYT-103 was more accurate compared with CT scan, but when value of the
scan was examined with respect to its potential contribution to patie
nt management, it was beneficial in only 13 percent of patients. Furth
er refinements may enhance the value of antibody imaging techniques.